JPRN-UMIN000017644已完成未知
The prospective, multicenter Stop Tyrosine Kinase Inhibitor trial of pediatric chronic myeloid leukemia with sustained complete molecular response (STKI-14) - The prospective, multicenter Stop TKI trial of pediatric CML (STKI-14)
Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)0 个研究点目标入组 25 人开始时间: 2015年6月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1years-old 至 20years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of blast crisis 2) CNS hemorrage more than grade 3 of CACAE v4.0 3) Uncontrolled infection, including active tuberculosis and positive of HIV antibody. 4) Pregnancy or high possibility of pregnancy and giving suck woman. 5) History of congenital or acquired immunodeficiency. 6) QTfc, corrected by Friderics formula as QTfc = QT/RR*1/3, is more than 0.45 seconds. 7) Any inappropriate status judged by physician.
研究者
相似试验
进行中（未招募）
1 期
Continuing Access to the Tyrosine Kinase Inhibitor of VEGFR-2, AG-013736 (A406) for Patients Previously Receiving AG-013736 in Clinical TrialsPatients who have been treated in previous AG-013736 oncology studiesEUCTR2005-000051-15-DEPfizer Pharma GmbH50
进行中（未招募）
1 期
Continuing Access to AG-013736 (A406) for Patients Previously Receiving AG-013736 in Clinical TrialsEUCTR2005-000051-15-CZPfizer Inc., 235 East 42nd Streeet, New York, NY 1001766
进行中（未招募）
不适用
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)MedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2010-022946-25-Outside-EU/EEAChildren's Oncology Group195
进行中（未招募）
不适用
CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2,AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 INCLINICAL TRIALSPatients who have been treated in previous AG-013736 oncology studies.MedDRA version: 14.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000051-15-ITPFIZER INC.39
招募中
不适用
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitorsmalignancies10027655cancerNL-OMON53128Antoni van Leeuwenhoek Ziekenhuis1,500